Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press86310.36691/RJA863ArticlesСтатьиTREATMENT OF URTICARIA: TODAY AND TOMORROWЛЕЧЕНИЕ КРАПИВНИЦЫ: СЕГОДНЯ И ЗАВТРА(Часть II)BorzovaElena YuБорзоваЕлена Ю

Университетская больница Норфолка и Норвича

elena.borzova@nnuh.nhs.ukGrattanClive HГраттанК H

Norfolk and Norwich University Hospital

Университетская больница Норфолка и Норвича

Университетская больница Норфолка и НорвичаNorfolk and Norwich University HospitalУниверситетская больница Норфолка и Норвича1512201076NO6 (2010)№6 (2010)51310032020Copyright ©; 1970, Pharmarus Print MediaCopyright ©; 1970, Фармарус Принт Медиа1970Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/863

Urticaria is a common disorder with diverse clinical presentations. Correct recognition of the different clinical patterns helps clinical assessment and treatment. The management of urticaria involves recognition of relevant disease associations, treatment of any identifiable external causes including infection, avoidance of drug, food and physical triggers and the appropriate use of pharmacological therapies. These can be divided into first, second and third line approaches. The choice of treatment will be influenced by many factors including drug licensing, safety, pattern of disease, its severity, pharmacoeconomic considerations and patient preference. Possible new therapeutic approaches on the horizon include new H1 antihistamines, H4 receptor antagonists, a histidine decarboxylase inhibitor under development and biological agents that target histamine - releasing autoantibody production and function.

Крапивница - распространенное заболевание, характеризующееся возникновением на коже зудящих волдырей. Точная диагностика разных патофизиологических форм может помочь в выборе наиболее эффективного метода лечения. Ведение больных подразумевает устранение любых выявленных внешних причин заболевания, в том числе инфекций, исключение провоцирующих факторов (медикаментов, продуктов питания и физических триггеров) и эффективное использование лекарственных средств. Лечение больных крапивницей можно подразделить на терапию первой, второй и третьей линий. На выбор метода лечения влияет много факторов, включая лицензионный статус лекарств, их безопасность, клиническую картину и тяжесть заболевания, предпочтения пациента. Возможные новые методы лечения включают новые Н1-антигистаминные и Н4-антигистаминные препараты, разрабатываемый ингибитор гистидиндекарбоксилазы и биологические препараты, воздействующие на образование и функцию гистаминолиберирующих аутоантител.

urticariaangioedemaurticarial vasculitistreatmentantihistaminesanti-leukotrienesimmunotherapyperspectivesкрапивницаангиоотекуртикарный васкулитлечениеантигистаминные препаратыантилейкотриеновые препаратыиммунотерапияперспективыSimon H.U., Spath P.J. IVIG-mechanisms of action Allergy. 2003, v. 58 (7), p. 543-552.O'Donnell B.F., Barr R.M., Black A.K. et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br. J. Dermatol. 1998, v. 138 (1), p. 101-106.Klote M.M., Nelson M.R., Engler R.J. Autoimmune urticaria response to high-dose intravenous immunoglobulin. Ann. Allergy Asthma Immunol. 2005, v. 94 (2), p. 307-308.Grattan C.E., Francis D.M., Slater N.G. et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet. 1992, v. 339 (8801), p. 1078-1080.Bernstein J.A., Garramone S.M., Lower E.G. Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann. Allergy Asthma Immunol. 2002, v. 89 (2), p. 212-214.Frieling U., Luger T.A. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases. Clin. Exp. Dermatol. 2002, v. 27 (7), p. 562-570.Gach J.E., Sabroe R.A., Greaves M.W., Black A.K. Methotrexateresponsive chronic idiopathic urticaria: a report of two cases. Br. J. Dermatol. 2001, v. 145 (2), p. 340-343.Godse K. Methotrexate in autoimmune urticaria. Ind. J. Dermatol. Venerol. Leprol. 2004, v. 70 (6), p. 377.Dice J.P. Physical urticaria. Immunol. Allergy Clin. North Am. 2004, v. 24 (2), p. 225-246.Grattan C., Powell S., Humphreys F. British Association of Dermatologists. Management and diagnostic guidelines for urticaria and angioedema. Br. J. Dermatol. v. 144 (4), p. 708-714.Zuberbier T., Bindslev-Jensen C., Canonica W. et al. EAACIGA2LEN/EDF. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy. 2006, v. 61 (3), p. 321-331.Kontou-Fili K., Maniatakou G., Demaka P., Gonianakis M. et al. Therapeutic effects of cetirizine in delayed pressure urticaria: clinicopathologic findings. J. Am. Acad. Dermatol. 1991, v. 24 (6 Pt. 2), p. 1090-1093.Juhlin L. Alternative treatments for severely affected patients with urticaria. J. Investig. Dermatol. Symp. Proc. 2001, v. 6 (2), p. 157-159.Vena G.A., Cassano N., Filieri M., Filotico R. et al. Fexofenadine in chronic idiopathic urticaria: a clinical and immunohistochemical evaluation. Int. J. Immunopathol. Pharmacol. 2002, v. 15 (3), p. 217-224.Boyce J.A. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J. Allergy Clin. Immunol. 2006, v. 117 (6), p. 1415-1418.Agostoni A., Aygoren-Pursun E., Binkley K.E. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J. Allergy Clin. Immunol. 2004, v. 114 (3 Suppl), p. 51-131.Zuraw B.L. Novel therapies for hereditary angioedema. Immunol. Allergy Clin. North Am. 2006, v. 26 (4), p. 691-708.Heymann W.R. Acquired angioedema. J. Am. Acad. Dermatol. 1997, v. 36 (4), p. 611-615.Frigas E., Nzeako U.C. Angioedema. Pathogenesis, differential diagnosis, and treatment. Clin. Rev. Allergy Immunol. 2002, v. 23 (2), p. 217-231.Kaplan A.P., Greaves M.W. Angioedema. J. Am. Acad. Dermatol. 2005, v. 53 (3), p. 373-388.Agostoni A., Cicardi M. Drug-induced angioedema without urticaria. Drug Saf. 2001, v. 24 (8), p. 599-606.Tan E.K., Grattan C.E. Drug-induced urticaria. Expert. Opin. Drug Saf. 2004, v. 3 (5), p. 471-484.Zingale L.C., Beltrami L., Zanichelli A. et al. Angioedema without urticaria: a large clinical survey., CMAJ. 2006, v. 175 (9), p. 1065-1070.Cicardi M., Bergamaschini L., Zingale L.C. et al. Idiopathic nonhistaminergic angioedema. Am. J. Med. 1999, v. 106 (6), p. 650-654.Kobza Black A. Urticarial vasculitis. Clin. Dermatol. 1999, v. 17 (5), p. 565-569.Soter N.A. Urticarial venulitis. Dermatologic therapy. 2000, v. 13, p. 400-408.Venzor J., Lee W.L., Huston D.P. Urticarial vasculitis. Clin. Rev. Allergy Immunol. 2002, v. 23 (2), p. 201-216.Shinkai K., McCalmont T.H., Leslie K.S. Cryopyrin-associated periodic syndromes. Clin. Exp. Dermatol., in press.Leslie K.S., Lachmann H.J., Bruning E. et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch. Dermatol. 2006, v. 142 (12), p. 1591-1597.Thompson A.K., Finn A.F., Schoenwetter W.F. Effect of 60 mg twice daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J. Am. Acad. Dermatol. 2000, v. 43 (1 Pt. 1), v. 24-30.Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin. Exp. Dermatol. 2006, v. 32 (1), p. 34-38.Simons F.E. Advances in H1-antihistamines. N. Engl. J. Med. 2004, v. 351 (21), p. 2203-2217.Golightly L.K., Greos L.S. Second generation antihistamines. Actions and efficacy in the management of allergic disorders. Drugs. 2005, v. 63, p. 341-384.Kapp A., Demarteau N. Cost Effectiveness of Levocetirizine in Chronic Idiopathic Urticaria: A Pooled Analysis of Two Randomised Controlled Trials Clinical. Drug Investigation. 2006, v. 26 (1), p. 1-11.Salmun L.M. Antihistamines in late-phase clinical development for allergic disease. Expert. Opin. Investig. Drugs. 2002, v. 11 (2), p. 259-273.Picado C. Rupatadine: pharmacological profile and its use in the treatment of allergic disorders. Expert. Opin. Pharmacother. 2006, v. 7 (14), p. 1989-2001.Oppenheimer J.J., Casale T.B. Next generation antihistamines: therapeutic rationale, accomplishments and advances. Expert. Opin. Investig. Drugs. 2002, v. 11 (6), p. 807-817.Fung-Leung W.P., Thurmond R.L., Ling P., Karlsson L. Histamine H4 receptor antagonists: the new antihistamines? Curr. Opin. Investig. Drugs. 2004, v. 5 (11), p. 1174-1183.Dunford P.J., Williams K.N., Desai P.J. et al. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J. Allergy Clin. Immunol. 2007, v. 119 (1), p. 176-183.Papadopoulou N., Kalogeromitros D., Staurianeas N.G. et al. Corticotropin-releasing hormone receptor-1 and histidine decarboxylase expression in chronic urticaria. J. Invest. Dermatol. 2005, v. 125 (5), p. 952-955.Greaves M.W. The immunopharmacology of skin inflammation: the future is already here- Br. J. Dermatol. 2000, v. 143 (1), p. 47-52.Mankad V.S., Burks A.W. Omalizumab: other indications and unanswered questions. Clin. Rev. Allergy Immunol. 2005, v. 29 (1), p. 17-30.Boyce J.A. Successful treatment of cold induced urticaria/anaphylaxis with anti IgE. J. Allergy Clin. Immunol. 2006, v. 117 (6), p. 1415-1418.Fatourechi M.M., Azhary R.A., Gibson L.E. Rituximab: applications in dermatology. Int. J. Dermatol. 2006, v. 45 (10), p. 1143-1155.Mallipeddi R., Grattan C.E.H. Lack of response of severe steroid dependent urticaria to rituximab. Clin. Exp. Dermatology, in press.